Company Encyclopedia
View More
name
Inotiv
NOTV.US
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line.
745.46 B
NOTV.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking55/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-48.46%E
    • Profit Margin-15.63%D
    • Gross Margin25.96%C
  • Growth ScoreC
    • Revenue YoY0.85%C
    • Net Profit YoY20.41%B
    • Total Assets YoY-1.92%D
    • Net Assets YoY-21.04%E
  • Cash ScoreD
    • Cash Flow Margin-639.91%E
    • OCF YoY0.85%C
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreE
    • Gearing Ratio81.07%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025

    WEST LAFAYETTE, Ind., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Inotiv, Inc. ( NASDAQ: NOTV ) ( the "Company", or "Inotiv" ) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and ...

    GlobeNewswire·
    US
    NOTV
    -3.89%
    GlobeNewswire·
    US
    NOTV
    -3.89%

    Lake Street Keeps Their Buy Rating on Inotiv (NOTV)

    Lake Street analyst Frank Takkinen reiterated a Buy rating on Inotiv (NOTV) with a price target of $5.00. Takkinen, who covers the Healthcare sector, has an average return of 0.1% and a 40.10% success rate on recommended stocks. The analyst consensus on Inotiv is a Moderate Buy with an average price target of $5.00.

    Tip Ranks·
    US
    NOTV
    -3.89%
    Tip Ranks·
    US
    NOTV
    -3.89%

    Inotiv Reveals Preliminary Q4 And FY2025 Revenue, Stock Jumps

    Inotiv, Inc. (NOTV) shares surged over 23% after releasing preliminary Q4 and FY2025 revenue results. The company expects Q4 revenue between $137.5M and $138.5M, a 6% increase from the previous year, and FY2025 revenue between $512.5M and $513.5M, a 4.5% annual growth. Strong growth in Discovery and Safety Assessment services was noted. The stock rose to $0.84 in overnight trading, up 23.53% from the previous close.

    rttnews·
    US
    NOTV
    -3.89%
    rttnews·
    US
    NOTV
    -3.89%

    Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results

    Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million ...

    GlobeNewswire·
    US
    NOTV
    -3.89%
    GlobeNewswire·
    US
    NOTV
    -3.89%

    Inotiv rises after strong preliminary FY revenue forecast 

    ** Shares of contract research firm Inotiv rise 20.3% to 83 cents in extended trading** Co says it expects preliminary 2025 revenue in the range of $512.5 million to $513.5 million, analysts on average expect FY revenue of $508.25 million, according to data compiled by LSEG** Co expects prelim Q4 revenue between $137.5 million and $138.5 million, vs analysts' estimate of $133.36 million** NOTV stock down 83.4% YTD

    Reuters·
    US
    NOTV
    -3.89%
    Reuters·
    US
    NOTV
    -3.89%